{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (6''S'',8''R'',9''S'',10''R'',13''S'',14''S'',17''S'')-17-hydroxy-6,10,13-trimethyl-17-prop-1-ynyl-2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-cyclopenta[''a'']phenanthren-3-one
| image = Dimethisterone.svg
| alt = Skeletal formula of dimethisterone
| width = 
| image2 = Dimethisterone 3D ball.png
| alt2 = Ball-and-stick model of the dimethisterone molecule
| width2 = 

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 79-64-1
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 6607
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 6357
| UNII = OIC9M646C5

<!--Chemical data-->
| C=23 | H=32 | O=2
| molecular_weight = 340.50 g/mol
| smiles = CC#C[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C)C)O
| StdInChI_Ref = 
| StdInChI = 1S/C23H32O2/c1-5-9-23(25)12-8-19-17-13-15(2)20-14-16(24)6-10-21(20,3)18(17)7-11-22(19,23)4/h14-15,17-19,25H,6-8,10-13H2,1-4H3/t15-,17+,18-,19-,21+,22-,23-/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = LVHOURKCKUYIGK-RGUJTQARSA-N
| synonyms = Dimethindrone
}}

'''Dimethisterone''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) (brand names '''Lutagan''', '''Secrosteron'''), also known as '''6α,21-dimethylethisterone''', is a [[steroid]]al [[progestin]] related to [[ethisterone]] (17α-ethinyltestosterone).<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA430|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=430–}}</ref><ref name="PaolettiPasetto2012">{{cite book|author1=Rodolfo Paoletti|author2=N. Pasetto|author3=J.L. Ambrus|title=The Menopause and Postmenopause: The Proceedings of an International Symposium held in Rome, June 1979|url=https://books.google.com/books?id=wZF9CAAAQBAJ&pg=PT374|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-7230-1|pages=374–}}</ref><ref name="SurwitAlberts2012">{{cite book|author1=Earl A. Surwit|author2=David Alberts|title=Endometrial Cancer|url=https://books.google.com/books?id=jbshBQAAQBAJ&pg=PA11|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4613-0867-6|pages=11–}}</ref><ref name="Patterson2012">{{cite book|author=Richard Patterson|title=Drugs in Litigation: Damage Awards Involving Prescription and Nonprescription Drugs|url=https://books.google.com/books?id=A_2nthjHDjAC&pg=PT483|date=21 December 2012|publisher=LexisNexis|isbn=978-0-327-18698-4|pages=483–484}}</ref> It was developed by the [[Great Britain|British]] [[pharmaceutical company]] [[British Drug Houses]] (which subsequently merged with [[Merck KGaA]]) and was first reported in the medical literature in 1959,<ref name="Elks2014" /><ref name="pmid13814263">{{cite journal | vauthors = DAVID A, FELLOWES KP, MILLSON DR | title = Some biological properties of dimethisterone "secrosteron" a new orally active progestational agent | journal = The Journal of Pharmacy and Pharmacology | volume = 11 | issue = | pages = 491–5 | year = 1959 | pmid = 13814263 | doi = | url = }}</ref> with introduction for medical use as '''Secrosteron''' following in the same year.<ref name="Applezweig1962">{{cite book|author=Norman Applezweig|title=Steroid Drugs|url=https://books.google.com/books?id=SIhLAAAAYAAJ|year=1962|publisher=Blakiston Division, McGraw-Hill|pages=101–102|quote=At The British Drug Houses, Ltd., V. Petrow and his group decided that substitution at the 6 position should help to strengthen the progesterone molecule. They prepared a series of 6α and 6β derivatives and, finding enhancement with 6α-methyl, proceeded to modify ethisterone and finally produced 6α,21-dimethylethisterone, which proved to have twelve times the oral activity of ethisterone. This latter product is marketed by British Drug Houses under the name of Secrosteron.}}</ref><ref name="Juta1959">{{cite book|title=Medical Proceedings: A South African Journal for the Advancement of Medical Science|url=https://books.google.com/books?id=r9tDAQAAIAAJ|year=1959|publisher=Juta and Company|page=269|quote=Secrosteron a new oral progestational substance British Drug Houses (South Africa) (Pty.) Ltd., announce the introduction of Secrosteron, a new fundamental discovery from the Research Laboratories of the British Drug Houses Ltd., London.}}</ref>

Dimethisterone was derived from modification of ethisterone via introduction of [[methyl group]]s at the C6α and C21 positions.<ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1316|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=1316–}}</ref><ref name="Applezweig1962" /> Relative to ethisterone, it is 12 times as potent [[oral administration|orally]] as a [[progestogen]] in animals ([[Clauberg test]]),<ref name="pmid13814263" /><ref name="Applezweig1962" /> and, unlike ethisterone,<ref name="EglenJuchau2012">{{cite book |author1=Richard M. Eglen |author2=Mont R. Juchau |author3=Gillian Edwards |author4=Arthur H. Weston |author5=Helen Wise |author6=M. D. Murray |author7=D. Craig Brater |author8=Olivier Valdenaire |author9=Philippe Vernier |author10=Annemarie Polak |title=Progress in Drug Research: Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques |url=https://books.google.com/books?id=fzUDCAAAQBAJ&pg=PA72 |date=6 December 2012 |publisher=Birkhäuser |isbn=978-3-0348-8863-9 |pages=72–}}</ref> is a pure progestogen with no [[androgen]]ic (or [[estrogen]]ic) activity in animals even at very high doses (although some weak [[antimineralocorticoid]] activity was observed at high doses in animals).<ref name="pmid13814263" /><ref name="MorganJones1959">{{cite book|title=Vademecum International|url=https://books.google.com/books?id=xRhtAAAAMAAJ|year=1959|publisher=J. Morgan Jones Publications.|page=90|quote=Secrosteron (dimethisterone) is an orally active purely progestational agent twelve times as potent as ethisterone.}}</ref><ref name="JUCKER2013">{{cite book|author=JUCKER|title=Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques|url=https://books.google.com/books?id=BH4ECAAAQBAJ&pg=PA166|date=8 March 2013|publisher=Birkhäuser|isbn=978-3-0348-7053-5|pages=166–}}</ref> However, in spite of its improved potency over ethisterone, it is a weak progestogen relative to most other progestins,<ref name="SurwitAlberts2012" /> in fact one of the weakest known.<ref name="PaolettiPasetto2012" />

Dimethisterone was introduced in the [[United States]] as an [[oral contraceptive]] in combination with high doses of [[ethinylestradiol]] under the brand name '''Oracon''' (25&nbsp;mg dimethisterone, 100&nbsp;μg ethinylestradiol) in 1965.<ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1331|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=1331–}}</ref> Due to the fact that it contains a weak progestogen in combination with a large dose of a potent [[estrogen]], this preparation was eventually found to be associated with a substantially increased risk of [[endometrial cancer]] in women, and is now no longer marketed.<ref name="BarakatMarkman2009">{{cite book|author1=Richard R. Barakat|author2=Maurie Markman|author3=Marcus Randall|title=Principles and Practice of Gynecologic Oncology|url=https://books.google.com/books?id=hsMne5mAXSIC&pg=PA5|year=2009|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-7845-9|pages=5–|quote=Studies have shown that women who used Oracon, a sequential preparation that employed dimethisterone (weak progestogen) with a large dose of a potent estrogen (ethinyl estradiol), had substantially elevated risks of uterine cancer (6,21). The risk associated with the use of other sequential oral contraceptives remains unclear, mainly because these drugs are no longer  marketed.}}</ref>

The improved potency of dimethisterone due to 6α-methylation reportedly served as the basis for the [[chemical synthesis|synthesis]] of [[medroxyprogesterone acetate]].<ref name="Applezweig1962" /> Whereas [[hydroxyprogesterone acetate]] (the 6α-demethylated [[structural analog|analogue]] of medroxyprogesterone acetate) is around twice as potent as ethisterone orally,<ref name="pmid13475464">{{cite journal | vauthors = DAVIS ME, WIED GL | title = 17-alpha-HYDROXYPROGESTERONE acetate; an effective progestational substance on oral administration | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 17 | issue = 10 | pages = 1237–44 | year = 1957 | pmid = 13475464 | doi = 10.1210/jcem-17-10-1237 | url = | quote = It is the purpose of this paper to introduce and describe a new steroid for oral administration, 17-a-hydroxyprogesterone acetate*, and to compare it with the most widely used oral substance with progestational properties, 20,21-anhydro-17-/3-hydroxyprogesterone. * Prodox, Upjohn Co., Kalamazoo, Michigan [...] It was found that 17-a-hydroxyprogesterone acetate has a progestational activity which is at least twice that of anhydrohydroxyprogesterone.}}</ref> medroxyprogesterone acetate shows 10 to 25 times the potency of ethisterone.<ref name="Applezweig1962" />

==See also==
* [[Norethisterone]]

==References==
{{Reflist|2}}

{{Progestogens}}
{{Progestogenics}}
{{Mineralocorticoidics}}

[[Category:Alkynes]]
[[Category:Androstanes]]
[[Category:Antimineralocorticoids]]
[[Category:Progestogens]]